Claire E. Wainwright spends much of her time researching Cystic fibrosis, Microbiology, Pseudomonas aeruginosa, Internal medicine and Randomized controlled trial. The various areas that Claire E. Wainwright examines in her Cystic fibrosis study include Lung and Immunology. Her Microbiology research incorporates themes from Pseudomonadaceae, Pulsed-field gel electrophoresis, Molecular typing, Polymerase chain reaction and Virulence.
Her Pseudomonas aeruginosa research incorporates elements of Sputum, Strain, Genotype and Pathology. Her Internal medicine research integrates issues from Gastroenterology and Surgery. Her Randomized controlled trial research is multidisciplinary, incorporating elements of Bronchiolitis and Anesthesia.
Claire E. Wainwright focuses on Cystic fibrosis, Internal medicine, Pseudomonas aeruginosa, Microbiology and Gastroenterology. Claire E. Wainwright works mostly in the field of Cystic fibrosis, limiting it down to topics relating to Bronchoalveolar lavage and, in certain cases, Bronchiectasis. Her Internal medicine study combines topics from a wide range of disciplines, such as Endocrinology and Surgery.
In her work, Gene mutation is strongly intertwined with Antibiotic resistance, which is a subfield of Pseudomonas aeruginosa. Her Microbiology research is multidisciplinary, incorporating perspectives in Stenotrophomonas maltophilia, Pulsed-field gel electrophoresis, Mycobacterium abscessus and Gene, Virulence. Her work on Lumacaftor as part of general Ivacaftor study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
Her main research concerns Cystic fibrosis, Internal medicine, Ivacaftor, Gastroenterology and In patient. Claire E. Wainwright has researched Cystic fibrosis in several fields, including Body mass index, Bronchiectasis, Mutation, Pseudomonas aeruginosa and Lung function. Her Pseudomonas aeruginosa research includes themes of Antibiotic resistance, Carbapenem and Increased risk.
Her studies in Ivacaftor integrate themes in fields like Discontinuation and Phases of clinical research. Her Cystic fibrosis transmembrane conductance regulator study which covers Tolerability that intersects with Interim analysis. Claire E. Wainwright has included themes like Lung and Atelectasis in her Clinical research study.
Her primary areas of study are Internal medicine, Cystic fibrosis, Gastroenterology, Ivacaftor and Bronchoalveolar lavage. Her biological study spans a wide range of topics, including Phenotype, Aspergillus and Empyema. Her Cystic fibrosis study integrates concerns from other disciplines, such as Microbiology, Bacteria, Staphylococcus aureus and Transmission, Infection transmission.
Her Gastroenterology study combines topics in areas such as Discontinuation and Mutation. Her Ivacaftor study incorporates themes from Clinical endpoint, Adverse effect and Phases of clinical research. Her study in Bronchoalveolar lavage is interdisciplinary in nature, drawing from both Pseudomonas aeruginosa, Fungal pathogen, Positive culture and Bronchiectasis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
Bonnie W. Ramsey;Jane Davies;N. Gerard McElvaney;Elizabeth Tullis.
The New England Journal of Medicine (2011)
Nebulised hypertonic saline solution for acute bronchiolitis in infants
Linjie Zhang;Raúl A Mendoza-Sassi;Claire Wainwright;Terry P Klassen.
Cochrane Database of Systematic Reviews (2013)
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation
Jane C. Davies;Jane C. Davies;Claire E. Wainwright;Gerard J. Canny;Mark A. Chilvers.
American Journal of Respiratory and Critical Care Medicine (2013)
Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.
Josephine M Bryant;Josephine M Bryant;Dorothy M Grogono;Dorothy M Grogono;Daniela Rodriguez-Rincon;Isobel Everall.
Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway Infection
Alexandra L. Quittner;Avani C. Modi;Claire Wainwright;Kelly Otto.
A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis.
Claire Wainwright;Luis Altamirano;Marise Cheney;Joyce Cheney.
The New England Journal of Medicine (2003)
Genetic modifiers of liver disease in cystic fibrosis.
Jaclyn R. Bartlett;Kenneth J. Friedman;Simon C. Ling;Rhonda G. Pace.
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled, phase 3 trial
Felix Ratjen;Christopher Hug;Gautham Marigowda;Simon Tian.
The Lancet Respiratory Medicine (2017)
Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: A randomized trial
Claire E. Wainwright;Suzanna Vidmar;David S. Armstrong;Catherine A. Byrnes.
Nebulized hypertonic saline solution for acute bronchiolitis in infants: [Intervention Review]
Linjie Zhang;Raul A. Mendoza-Sassi;Claire Wainwright;Terry P. Klassen.
Cochrane Database of Systematic Reviews (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: